Skip to content

Sera Prognostics SERA Available for sale investments

Available for sale investments at other companies

Natera, Inc. logo
Natera, Inc.NTRA
Pediatrix Medical Group logo
Pediatrix Medical GroupMD

Other financials

Income statement

See full
Revenue$14.0K-63.2%
Operating income-$9.4M-1.2%
Net income-$8.4M-2.6%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$4.2M-20.2%
Total debt$2.5M+286%
Total equity$67.6M-28.7%
Total assets$93.5M-20.8%

Cash flow

See full
Operating cash flow-$8.8M-16.2%
CapEx$8.0K+167%
Free cash flow-$8.8M-16.2%

Valuation

See full
Market cap$71.27M+5.0%
Enterprise value$69.6M+9.6%
P/S1,250.3×+622×

Profitability

See full
Operating margin-64,235.1%-8,092,342pp
Net margin-56,386%+1,586,573pp
FCF margin-48,377.2%-673,104pp

Returns & leverage

See full
Return on equity-39.6%-1.6pp
Debt / equity0.0×
Current ratio2.1×+0.1×

Where this comes from

Reported directly by Sera Prognostics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Sera Prognostics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sera Prognostics's available for sale investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sera Prognostics's available for sale investments?
Sera Prognostics (SERA) reported available for sale investments of $82.59M in Q1 2026.
How has Sera Prognostics's available for sale investments changed year-over-year?
Sera Prognostics's available for sale investments decreased by 24.2% year-over-year, from $108.97M to $82.59M.
What is the long-term trend for Sera Prognostics's available for sale investments?
Over 4 years (2021 to 2025), Sera Prognostics's available for sale investments has grown at a 3.2% compound annual growth rate (CAGR), from $81.03M to $91.84M.